Clinical Trial Update: Treatment of an Inherited Ventricular Arrhythmia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial for catecholaminergic polymorphic ventricular tachycardia type 1 sponsored by RyCarma Therapeutics has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catecholaminergic Polymorphic Ventricular Tachycardia Type

Snippet

Sponsor: RyCarma Therapeutics, Inc. | Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 | Phase 2 | Status: TERMINATED